Protein Tyrosine Phosphatase, Non-Receptor Type 2
"Protein Tyrosine Phosphatase, Non-Receptor Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of non-receptor protein tyrosine phosphatase that is closely-related to PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1. Alternative splicing of the mRNA for this phosphatase results in the production at two gene products, one of which includes a C-terminal nuclear localization domain that may be involved in the transport of the protein to the CELL NUCLEUS. Although initially referred to as T-cell protein tyrosine phosphatase the expression of this subtype occurs widely.
MeSH Number(s)
D08.811.277.352.650.775.300.200
D12.644.360.585.200
D12.776.476.564.200
Below are MeSH descriptors whose meaning is more general than "Protein Tyrosine Phosphatase, Non-Receptor Type 2".
Below are MeSH descriptors whose meaning is more specific than "Protein Tyrosine Phosphatase, Non-Receptor Type 2".
This graph shows the total number of publications written about "Protein Tyrosine Phosphatase, Non-Receptor Type 2" by people in Harvard Catalyst Profiles by year, and whether "Protein Tyrosine Phosphatase, Non-Receptor Type 2" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 3 | 0 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
Below are the most recent publications written about "Protein Tyrosine Phosphatase, Non-Receptor Type 2" by people in Profiles.
-
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2022 02 03; 139(5):717-731.
-
PTPN2 mutations cause epithelium-intrinsic barrier loss that synergizes with mucosal immune hyperactivation. J Clin Invest. 2021 09 01; 131(17).
-
Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature. 2020 07; 583(7814):90-95.
-
Functional informed genome-wide interaction analysis of body mass index, diabetes and colorectal cancer risk. Cancer Med. 2020 05; 9(10):3563-3573.
-
PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat Immunol. 2019 10; 20(10):1335-1347.
-
A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat Commun. 2019 04 10; 10(1):1668.
-
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017 07 27; 547(7664):413-418.
-
Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1-derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis-like and psoriasis-like dermatitis. J Allergy Clin Immunol. 2018 01; 141(1):137-151.
-
Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium. Sci Rep. 2017 04 11; 7(1):825.
-
Leptin and insulin act on POMC neurons to promote the browning of white fat. Cell. 2015 Jan 15; 160(1-2):88-104.